Stemedica
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions.
Team
Stemedica has a team of experienced scientists, management and technicians to progress our proprietary technology.
Technology
Stemedica’s proprietary platform technology produces multiple progenitor cell products that meet exacting quality standards required for a cGMP licensed facility.
Trials
Stemedica is currently advancing clinical trials in the United States for several critical medical conditions.
Latest News
Stemedica Cell Technologies Appoints Michael K. Steinhauser CEO and Interim Chairman of the Board
SAN DIEGO, California –May 31, 2023. The Board of Directors of Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant stem cells, announced today that it has appointed Michael K. Steinhauser as Chief Executive Officer and Interim Chairman of...
Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke
SAN DIEGO, California – January 19, 2023. Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant, allogeneic mesenchymal stem cells (itMSC), announced today that it has initiated its “PHASE IIB/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,...
DARIUS ANDERSON TO JOIN STEMEDICA BOARD OF DIRECTORS
Respected and seasoned business leader, investor and political strategist offers multiple talents to stem cell technologies company SAN DIEGO, March 30, 2022 /PRNewswire/ -- Stemedica Cell Technologies, Inc. ("Stemedica"), a San Diego-based biotech company...